Inhibition of glycolysis of tumor cells is one of the most conspicuous metabolic effects of carcinostatic alkylating agents.'-' This inhibition coincides with a profound diminution of the steady-state concentration of DPN of tumor cells, as observed by Roitt,3 and Holzer et al.,4 and amply confirmed by numerous investigators.5-11 The mechanism responsible for the decrease in DPN content of tumor cells by carcinostatic alkylating agents has been unknown. Holzer et al."2 13 suggested that carcinostatic alkylating agents inhibit at some point the biosynthesis of DPN. On the other hand, Green and Bodansky'4 as well as Hilz et al. 15 believe that an activation of DPNase is the primary reason for a decrease of DPN content of tumor cells. A hint regarding the mechanism of carcinostatic alkylating agents on glycolysis has already been provided by the work of Roitt,3 who found that nicotinic acid amide antagonizes the inhibitory effect of these drugs. Interpretation of this observation remains ambiguous, however, since nicotinic acid amide is a well-known biosynthetic precursor of DPN as well as an inhibitor of DPNase. We have reinvestigated this question with the aid of structural analogues of nicotinamide. In order to eliminate the uncertainty concerning the possible dual action of nicotinamide on DPN metabolism, DPNase inhibitors had to be found which could not serve as precursors of DPN. Two among the nicotinamide homologues tested (5-fluoro and 5-methyl nicotinamide) fulfilled this requirement; thus correlation was established between DPNase inhibition and the antagonistic effect of this inhibition on the glycolysis blocking action of a carcinostatic alkylating agent (Trenimon) in Ehrlich ascites tumor cells.
Materials and Methods.-Ehrlich ascites cells were harvested from mice 8-10 days after inoculation, filtered through gauze, centrifuged, and washed free of erythrocytes with 0.9 per cent NaCl. DPNase was extracted from tumor cells according to Hilz'5 and assayed as follows: 1/Amole of DPN, 50 Mmole of phosphate (pH 7.2), and 0.3 ml of enzyme extract were incubated in 1 ml vol for 30 min at 37°. The reaction was stopped by 1 ml 6 per cent HC104, and after deproteinization C104-was removed by solid KHCO3. DPN was assayed with alcohol dehydrogenase according to Warburg'6 and with the cyanide test of Colowick, Kaplan, and Ciotti.'7 1\Ianometric experiments were performed under conditions described by Kun, Talalay, and Williams-Ashman.18 Glucose (0.06 ml 40%) and 0.06 ml 0.1 per cent Trenimon solution were tipped in after 10 min temperature equilibration (37°C; gas phase CO2; Ringer-bicarbonate buffer of pH 6.0). Paper chromatography of pyridine derivatives was carried out with solvent C of Preiss and Handler,'9 and paper electrophoresis as described earlier.'3 Identification of pyridine nucleotide derivatives was accomplished by conversion to fluorescent derivatives with methylethyl-ketone and NH3 according to Kodicek and Table 1 . In order to clarify the specificity of action of Trenimon on tumor glycolysis, its effect on DPNase itself was also determined. A concentration of Trenimon twice as high as needed to inhibit completely glycolysis (1.7 X 10-4 M) had no appreciable effect on DPNase itself, but reduced DPN content to 7.4 per cent of controls, as shown in Table 2 . This table also illustrates the distribution of DPNase in tumor cells, which in preincubated cells is quantitatively accounted for in the microsomal fraction. It is also evident that the carcinostatic drug, when preincubated with tumor cells, apart from having no effect on DPNase, does not alter the intracellular distribution of this enzyme either. These results are in agreement with previous PROC. N. A. S. 
